Comparative Pharmacology
Head-to-head clinical analysis: MATULANE versus NOVANTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MATULANE versus NOVANTRONE.
MATULANE vs NOVANTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent